미국 - 영어 - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg - minocycline hydrochloride capsules, usp are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: ·     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox and tick fevers caused by rickettsiae. ·     respiratory tract infections caused by mycoplasma pneumoniae . ·     lymphogranuloma venereum caused by chlamydia trachomatis . ·   psittacosis (ornithosis) due to chlamydia psittaci. ·   trachoma caused by chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. ·     inclusion conjunctivitis caused by chlamydia trachomatis . ·     nongonococcal urethritis, endocervical, or rectal infections in adults caused by ureaplasma urealyticum or chlamydia trachomatis . ·     relapsing fever due to borrelia recurrentis . ·     chancroid caused by haemophilus ducreyi . ·     plague due to yersinia pestis . ·   tularemia due to francisella tularensis . ·     cholera cau

미국 - 영어 - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg - minocycline hydrochloride capsules, usp are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: ·     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox and tick fevers caused by rickettsiae. ·     respiratory tract infections caused by mycoplasma pneumoniae . ·     lymphogranuloma venereum caused by chlamydia trachomatis . ·   psittacosis (ornithosis) due to chlamydia psittaci. ·   trachoma caused by chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. ·     inclusion conjunctivitis caused by chlamydia trachomatis . ·     nongonococcal urethritis, endocervical, or rectal infections in adults caused by ureaplasma urealyticum or chlamydia trachomatis . ·     relapsing fever due to borrelia recurrentis . ·     chancroid caused by haemophilus ducreyi . ·     plague due to yersinia pestis . ·   tularemia due to francisella tularensis . ·     cholera cau

미국 - 영어 - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 50 mg - minocycline hydrochloride capsules, usp are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: minocycline hydrochloride capsules, usp are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: when penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: in acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides. in severe acne , minocycline may be useful adjunctive therapy. oral minocycline is indicated in the treatment of asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx. in order to preserve the usefulness of minocycline

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - minocycline hydrochloride dihydrate 57,93 mg - eq. minocycline 50 mg - film-coated tablet - 50 mg - minocycline hydrochloride 57.93 mg - minocycline

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - minocycline hydrochloride dihydrate - capsules modified release - 100 milligram(s) - tetracyclines; minocycline

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - minocycline hydrochloride dihydrate - modified-release capsule, hard - 100 milligram(s) - tetracyclines; minocycline

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

ltt pharma limited - minocycline hydrochloride - capsules modified release - 100 milligram(s) - tetracyclines; minocycline

미국 - 영어 - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 45 mg - minocycline hydrochloride extended-release tablets usp are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets usp did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets usp have not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14)] to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets usp should be used only as indicated [see warnings and precautions (5.11)] this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. teratogenic effects: pregnancy category d [see warnings and precautions (5.1) ] minocycline hydrochloride extended-release tablets s

미국 - 영어 - NLM (National Library of Medicine)

aurobindo pharma limited - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 45 mg - minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14)]. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see warnings and precautions (5.11)]. this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. teratogenic effects: pregnancy category d [see warnings and precautions (5.1)] minocycline hydrochloride extended-release tablets should n

미국 - 영어 - NLM (National Library of Medicine)

sandoz inc - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 45 mg - minocycline hydrochloride extended-release tablets  are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets  did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14) ]. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets  should be used only as indicated [see warnings and precautions (5.11) ]. this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. teratogenic effects: pregnancy category d [ see warnings and precautions (5.1)] minocycline hydrochloride extended-release tablets should not